Printable version

Bulletin du Cancer. Volume 98, Number 2, 154-63, Février 2011, Synthèse/General review

Résumé   Article gratuit

Author(s) : Mario Campone, Dominique Berton-Rigaud, Emmanuelle Bourbouloux, Sadot Sophie, Alain Zanetti, Jean-Sébastien Frenel

Summary : The molecular classification of Perou and S⊘rlie breast tumors has to streamline, systematize and make effective use of targeted therapies against specific molecular subtypes, including breast HER2 positive. Trastuzumab and lapatinib are currently the two therapies targeting HER2, which have demonstrated their effectiveness in clinical practice. This literature review aims to make the data points on pertinent and useful data for physicians in daily

Keywords : Her2, breast cancer, trastuzumab, lapatinib